Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. - Wikidata - wikimedia - TriplyDB

Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.

Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.

http://www.wikidata.org/entity/Q34035395

about

Effects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function A brief history of the development of antidepressant drugs: from monoamines to glutamate Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy Chronic Vortioxetine Treatment Reduces Exaggerated Expression of Conditioned Fear Memory and Restores Active Coping Behavior in Chronically Stressed Rats A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or ag A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults.Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus.Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats.Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters.Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine.Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism.New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine.Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder.Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Novel agents in development for the treatment of depression.Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder.Vortioxetine: a review of its use in major depressive disorder.Vortioxetine for the treatment of major depressive disorder.A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.The efficacy of vortioxetine for the treatment of major depressive disorder.Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder.Regional distribution of serotonergic receptors: a systems neuroscience perspective on the downstream effects of the multimodal-acting antidepressant vortioxetine on excitatory and inhibitory neurotransmission.CRF₂ receptor-deficiency reduces recognition memory deficits and vulnerability to stress induced by cocaine withdrawal.Task- and Treatment Length-Dependent Effects of Vortioxetine on Scopolamine-Induced Cognitive Dysfunction and Hippocampal Extracellular Acetylcholine in Rats.Neuroplasticity pathways and protein-interaction networks are modulated by vortioxetine in rodents.Effects of sertraline, duloxetine, vortioxetine, and idazoxan in the rat affective bias test.Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression.Vortioxetine: Clinical Pharmacokinetics and Drug Interactions.Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study.Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single- and Multiple-Dose Administration in Healthy Japanese Adults.Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls.Effects of lisdexamfetamine alone and in combination with s-citalopram on acetylcholine and histamine efflux in the rat pre-frontal cortex and ventral hippocampus.Vortioxetine: first global approval.Piromelatine ameliorates memory deficits associated with chronic mild stress-induced anhedonia in rats.Vortioxetine Treatment Reverses Subchronic PCP Treatment-Induced Cognitive Impairments: A Potential Role for Serotonin Receptor-Mediated Regulation of GABA Neurotransmission.A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction.

P2860

Q26783101-754BA9E8-5EEE-4916-A3A5-B18CF130CCF1 Q27028050-41A9187E-D2D6-4848-9E66-F5DFBF961D51 Q28083651-EDCB850D-E416-4257-B5E8-81314FA09572 Q33614804-D45C97C7-D2FB-46FB-80FA-BC629A19E9EF Q34041642-7D74469B-71B0-40FA-A913-435F1D027387 Q34172150-CC6B2228-0220-4A57-899D-9E02FBDD4B13 Q34505291-75354E8A-99FA-410D-AD13-D525FB4FD28B Q34559591-CDB360F3-D6B1-4CA8-81B1-0F40D1A6C6C3 Q34670569-E0254128-6512-4486-8697-220DC57F2F50 Q34671039-03C7A81D-8FC0-445A-B781-E7956156594D Q34671692-B7AA2D78-0B2B-497B-A7FB-C9B7530BB2D5 Q34676776-2C7C0C63-D92F-43DF-A6FF-F04B6617BFE3 Q35918863-152AF706-C206-4A5F-BBF1-61DE1E4D3E7E Q36821817-8933D3E1-B13B-4679-A2FB-9AD9C06AAED3 Q37601281-10E06A4A-E4F1-4781-853C-82734540ED41 Q38125568-87CBEF7D-41DE-49B3-A502-92A9B5FE5397 Q38156001-4E543117-2F01-49A6-A04A-81E936269B69 Q38164163-C95FBE0B-1CFE-4E93-95FD-2048E1B7AB24 Q38200656-7DB883BA-2968-483E-AC52-ADC1A3DFA2AC Q38242001-3E29E6E5-7CA4-45BA-AECF-91343AC7F9C8 Q38244159-962D2CF4-9377-445B-8779-5A481BD26F18 Q38249999-9B0D91F7-054E-4F2C-8248-4625C9864BCB Q38270790-150680B2-0562-45CB-9AF5-11A535F5A05A Q38506798-97167559-3771-49B0-9CB5-4F5384E9F730 Q38562129-2B991E40-190C-4486-BAD7-0D4FB1B448C1 Q39264722-A48F4DF8-CD97-45A9-96CB-1C9A0119427A Q39612025-0636CDD9-6376-4A9E-90E1-8D9CE68E342C Q41250682-1B63D932-4E5B-47F7-83FF-755F96E5348B Q47397404-4E79BAE9-8C55-4377-A0D2-B7ED2F707691 Q47425773-326F9216-E358-419E-BAC6-FADF1AF03B3C Q47692041-5D3B4775-63E2-4DCF-B11D-8CC8512212F7 Q47701615-1507E46C-03C2-4A24-8CFD-2452E02406B7 Q47716057-16CB76E2-1D72-4A39-8199-3770FBC12C12 Q47760557-5F167834-6D7D-4498-B641-ED971B57D891 Q47879105-56F8C0FB-9025-425E-8D19-9B9BDD80D750 Q48190973-7E255F6E-5C38-414F-BB3D-A3AFC75415F3 Q48390325-3DC7ABD5-DD64-4AC8-832A-A6F20B8D3558 Q48810717-8D6CA298-B8B1-4B6D-89A0-2AD8041BF6A9 Q52645959-C5366067-518D-4D5E-B8E5-0B85FF49504C Q55080678-BA6CF9BA-8CC6-4B56-AA18-184F388A1870

P2860

Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.

http://www.wikidata.org/entity/Q34035395

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.

@ast

Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.

@en

Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.

@nl

type

label

Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.

@ast

Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.

@en

Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.

@nl

prefLabel

Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.

@ast

Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.

@en

Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.

@nl

P1433

Q34035395-B25B8C98-B0C6-4704-AA75-0385ADDB512E

P1476

Q34035395-E12F835D-576A-4410-9FDC-FEE9DE21E5E8

P2093

Q34035395-2ED966F8-BACE-4DF5-AF8A-6969E32F74CF

Q34035395-3D12683F-4E92-4453-9633-5D15A10A4350

Q34035395-59BEF621-9320-4E12-9658-F581605781B3

Q34035395-7EF65EE3-BE74-4360-833A-F8C45343138B

Q34035395-838F48C7-E5B9-4C8D-AE28-E1751D0AA542

Q34035395-8E1C9505-D352-49B9-9735-0B566C2C6325

Q34035395-8F79C187-CD0B-463F-B5A0-450AE4FF96A2

Q34035395-AA749EE5-EF4E-4DCC-AD7F-3D0ADE127D64

P304

Q34035395-093FADCF-A1D4-4080-AD91-FA87017095C7

P31

Q34035395-E2CAEF48-25BF-424F-AE2B-4CB98104CB20

P356

Q34035395-89D4081A-9514-4B54-9DFB-DA7D082837CF

P407

Q34035395-ABB07216-2DD9-45DE-BE34-2E602B61D427

P478

Q34035395-5097CD75-7C24-44C0-B642-E7CE5BDA8494

P577

Q34035395-5307B7E3-BD8D-4CAC-9E19-5065C03BB675

P5875

Q34035395-D904D477-B734-462E-B498-0987E725989D

P698

Q34035395-50E3EE10-EE6A-471C-8917-3427DB208983

P921

Q34035395-101DA722-2BF2-42B0-94BC-1558709CEACA

P356

J.PBB.2013.01.019

P1433

Pharmacology, Biochemistry and Behavior

P1476

Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.

@en

P2093

Arne Mørk

http://www.w3.org/2001/XMLSchema#string

Connie Sanchez

http://www.w3.org/2001/XMLSchema#string

Crista Trippodi-Murphy

http://www.w3.org/2001/XMLSchema#string

Liliana P Montezinho

http://www.w3.org/2001/XMLSchema#string

Maria Gulinello

http://www.w3.org/2001/XMLSchema#string

Niels Plath

http://www.w3.org/2001/XMLSchema#string

Silke Miller

http://www.w3.org/2001/XMLSchema#string

Yan Li

http://www.w3.org/2001/XMLSchema#string

P304

41-50

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.PBB.2013.01.019

http://www.w3.org/2001/XMLSchema#string

P407

P478

105

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235400514

http://www.w3.org/2001/XMLSchema#string

P698

23380522

http://www.w3.org/2001/XMLSchema#string

P921